URINARY INCONTINENCE TREATMENT DRUGS MARKET ANALYSIS

Global urinary incontinence treatment drugs market is estimated to be valued at US$ 4.41 Bn in 2023, and is expected to exhibit a CAGR of 3.4% during the forecast period (2023-2030).

Analysts’ Views on Global Urinary Incontinence Treatment Drugs Market:

Urinary incontinence (UI), or involuntary urine loss, is a highly prevalent issue that no one wants to discuss. Many people are too embarrassed to seek help because of the stigma that surrounds it. However, most illnesses that cause UI can be treated medically or through alternative means. Rising prevalence of urinary incontinence, growing geriatric population, and increasing developments by key market players are expected to boost the global urinary incontinence treatment drugs market  growth over the forecast period.

Figure 1. Global Urinary Incontinence Treatment Drugs Market Share (%), By Incontinence Type, 2023

To learn more about this report, request sample copy

Global Urinary Incontinence Treatment Drugs Market– Drivers

• Increasing number of regulatory approval for drugs: Increasing number of regulatory approval for drugs boosts the global urinary incontinence treatment drugs market growth. For instance, in December 2020, Urovant Sciences, a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved the New Drug Application (NDA) for 75 mg GEMTESA (vibegron), a beta-3 adrenergic receptor (β3) agonist,  once daily for the treatment of overactive bladder (OAB). The symptoms of urge urinary incontinence (UUI) includes  urgency and frequency of urination in adults. This approval marks the first new brand-name oral OAB drug approved by the U.S. FDA since 2012 and the first product approval for Urovant Sciences.
•  Increasing prevalence of urinary incontinence: Increasing prevalence of urinary incontinence is expected to boost demand for urinary incontinence treatment drugs, and this is  expecetd to drive the global urinary incontinence treatment drugs market growth. For instance, in September 2021,  according to a research study published by International Journal of Obstetrics and Gynaecology, , 24,985 women (mean age 41.9 years) were considered for the study. The follow-up rate was 55.5%, the mean follow-up time was 3.7 years. The standardized incidences of urinary incontinence (UI), stress urinary incontinence (SUI), urge urinary incontinence (UUI), and mixed urinary incontinence (MUI) were 21.2, 13.1, 3.0, and 5.1 per 1000 person-years, respectively.

Figure 2. Global Urinary Incontinence Treatment Drugs Market Share(%), By Region, 2023

To learn more about this report, request sample copy

Global Urinary Incontinence Treatment Drugs Market- Regional Analysis

Among region, North America is estimated to hold a dominant position in the global urinary incontinence treatment drugs market over the forecast period. North America is estimated to hold 33.5 % of the market share in 2023. North America urinary incontinence treatment drugs market is expected to witness significant growth in thenear future, driven by the high prevalence of orthopedic disorders and dysfunctions, favorable health reimbursement, and increased awareness. Increasing prevalence of neurological disorders is contributing to growth of the urinary incontinence treatment drugs market in North America region. For instance, in March 2021, according to the American Neurological Association (ANA), neurological diseases affect around 100 Mn people in the U.S. This significant number of patients with one neurological disorder is expected to increase number of neurosurgeries in the U.S., thereby, driving for the  urinary incontinence treatment drugs market growth in the U.S.

Global Urinary Incontinence Treatment Drugs Market– Impact of Coronavirus (COVID-19) Pandemic

• Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe, and the World Health Organization (WHO) declared it a public health emergency on January 30, 2020.
• COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Supply chain and manufacturing activities in India, Italy, Spain, the U.K., and the U.S. had been disrupted due to lockdowns implemented by governments, while countries such as Saudi Arabia, the U.A.E., Egypt, and others faced problems regarding the transportation of raw materials, chemicals, and finished products.
• The coronavirus, or COVID-19 outbreak, that started from Wuhan, China, has spread across continents, affecting various industries globally. The supply of key materials had been severely disrupted due to the forced quarantine and lack of labors and raw materials. As the link between regional warehouses was not smooth, the transportation of raw materials between regions could not be carried out successfully. This shortage of raw materials and components used for manufacturing of the drugs for the urinary incontinence treatment had affected the supply chain of the global urinary incontinence treatment drugs  market.
• Manufacturing sites, based in the worst hit countries, had been affected severely due to the severe shortage of medical resources and raw materials for the production of drugs and chemicals for urinary incontinence diagnosis. This led to disruption in global supply chain.
• For instance, in October 2020, according to the report published by the American Society for Microbiology, a life science membership organization, shortages of laboratory supply affected routine non-COVID-19 related laboratory procedures and diagnostic testing for a variety of other diseases such as urinary incontinence (UI), gastroenteritis, and others. In the U.S., the supply of laboratory operations and diagnostic testing for all kinds of diseases such as urinary incontinences and others,were also impacted. 

Global Urinary Incontinence Treatment Drugs Market Segmentation:

Global urinary incontinence treatment drugs market is segmented into incontinence type, drug class,  distribution channel, and  region.

• By incontinence type, the market is segmented into urge incontinence, stress incontinence, over-flow incontinence, mixed incontinence, and other incontinence type Out of which, the stress incontinence segment is expected to hold a dominant position in the global urinary incontinence treatment drugs market over  the forecast period due to increasing prevalence of stress incontinence due toincreasing desk bound lifestyle.
• By drug class, the market is segmented into anticholinergic/antispasmodic agents, skeletal muscle relaxants, antidepressants, alpha blockers, topical estrogens, and others. Out of which, antidepressants segment is expected to dominate the market over the forecast period due to huge demand for antidepressants drugs.
• By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Out of which,  hospital pharmacies segment  is expected to dominate the market over the forecast period due  to the advantages of hospital pharmacies such as easy medication access and over the counter drugs for individuals who are seeking treatment.
• Among all the segmentation, the drug class segment is expected to dominate the market over the forecast period due to increasing prevalence of urinary incontinence and thereby increasing demand for drugs.

Global Urinary Incontinence Treatment Drugs Market- Cross Sectional Analysis:

Key players are manufacturing urinary incontinence treatment drugs with advanced treatment methods in emerging economies, and this isexpected to boost demand for urinary incontinence treatment drugs market in the Middle East region. For instance, in December 2022, according to an article published by PubMed Central, a study was conducted in the United Arab Emirates which showed that the quality of life was impaired in an estimated 90% of patients with urinary incontinence. Therefore, the increasing burden of urinary incontinence among women and the aging population increases demand for urinary incontinence treatment drugs.

Global Urinary Incontinence Treatment Drugs Market: Key Developments

• In April 2022, Axonics, Inc., a medical technology company that develops and markets novel products to treat bladder and bowel dysfunction,  announced the launch of its direct-to-consumer television advertising campaign.
• In February 2022, Kimberly-Clark Corporation, the pioneer of menstrual hygiene products, announced that it had completed the acquisition of a majority stake in Thinx, Inc., an industry disruptor and leader in the reusable period and incontinence underwear category. The company made its first minority investment in Thinx in 2019.
• In January 2022, according to the data published by the International Trade Administration,  Chile healthcare expenses was US$ 13.50 billion in 2021, indicating increaseof 8.9% from expenses in 2020, which was US$ 12.29 billion.
• In March 2021, according to the data published by the National Center for Biotechnology Information,  urinary tract infection accounts for 1 Mn emergency department visits, and over 100,000 hospitalizations annually in the U.S.

Global Urinary Incontinence Treatment Drugs Market: Key Trends

• Increasing research and development: Increasing research and development activities for the novel drug treatment is expected to drive the global urinary incontinence treatment drugs market growth over the forecast period. For instance, in June 2022, Ipsen Pharma, a pharmaceutical company, announced that Dysport (abobotulinumtoxinA) had received a positive opinion in Europe for the treatment of urinary incontinence (UI) in adults with neurogenic detrusor overactivity (NDO) due to spinal cord injury (SCI) (traumatic or non-traumatic) or multiple sclerosis (MS), who regularly have a clean intermittent catheterization (CIC) performed.

Global Urinary Incontinence Treatment Drugs Market: Restraint

• Side effects associated with drugs: Side effects associated with drug treatment is expected to hinder the market growth over the forecast period. Approved drug such as Myrbetriq may cause side effects such as increased blood pressure, in which Myrbetriq may cause their blood pressure to increase or worsen if they had high blood pressure in the past. Moreover, Myrbetriq may increase the chance that patient will not be able to empty their bladder if they have bladder emptying disorder or if they are taking other medicines to treat overactive bladder.
• Counterbalance: Key players are focusing on developing treatment options with safety and cost effective methods, and this is expected to drive the market growth over the forecast period.

Global Urinary Incontinence Treatment Drugs Market - Key Players

Major players operating in the global urinary incontinence treatment drugs market include Johnson & Johnson, Pfizer Inc., Astellas Pharma, Inc., Allergan, Inc., Takeda Pharmaceutical Company Limited, Merck & Co., Inc., Sanofi S.A., IXALTIS, Bayer AG, elicept Therapeutics, Taiho Pharmaceutical, Cook MyoSite and Urovant Sciences GmbH. 

Definition: Bladder control problems are conditions that affect the way a person holds or releases urine. Accidental loss or leakage of urine, called urinary incontinence (UI), is one of the most common bladder control problems. UI is not a disease but a condition that may be related to another health problem or life event, such as prostate problems or pregnancy.